Back to Gastroenterology

OUR EXPERTISE AND AND SERVICES AVAILABLE IN

Emerging Gastroenterology

Overview

Spherix’s coverage of emerging gastroenterology indications focuses on evolving markets where a paradigm shift is expected in the coming years.

Services Available

Prepping for the pipeline

  • Celiac Disease (US)

  • Clostridioides Difficile (US)

  • Primary Biliary Cholangitis (US)

  • Eosinophilic Esophagitis (US)

  • Nonalcoholic Fatty Liver Disease/Non alcoholic Steatohepatitis (US)

Benchmarking new brand perfomance

  • APT 1011 (Ellodi) in Eosinophilic Esophagitis (US)*

  • Dupixent (Sanofi/Regeneron) in in Eosinophilic Esophagitis (US)*

  • Eohilia (Takeda) in in Eosinophilic Esophagitis (US)*

*Pending approvals and launch

Learn more about our services

  • HOW CAN WE PARTNER TOGETHER?

    Get more information on Emerging Gastroenterology Coverage